Extended Data Fig. 6: scRNA-seq and flow cytometry analyses of tumour-infiltrating REGNASE-1-null OT-I cells.
From: Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
a–e, scRNA-seq analysis of control-sgRNA- and Regnase-1-sgRNA-transduced OT-I cells isolated from TILs. Specifically, control-sgRNA- and Regnase-1-sgRNA-transduced OT-I cells were mixed and transferred into tumour-bearing mice, and tumour-infiltrating OT-I cells were isolated at day 7 for transcriptional profiling by scRNA-seq. t-SNE visualization of Pdcd1 (a, top), Havcr2 (a, bottom), Ifng (c, top), Gzmb (c, bottom), Batf (d) and Id2 (e) gene expression, and ‘CXCR5+ exhausted CD8 (Ahmed)12’ (b, top) and ‘CXCR5+ exhausted CD8 (Yu)13’ (b, bottom) gene signatures in individual cells. f, OT-I cells transduced with control sgRNA and Regnase-1 sgRNA were mixed and transferred into tumour-bearing mice (n = 5 mice; data from 1 representative mouse are shown), and tumour-infiltrating OT-I cells were analysed at day 7 for the expression of TOX, SLAMF6, CD127, KLRG1, TIM3 and PD-1 in TCF-1+ and TCF-1− cells of control-sgRNA- and Regnase-1-sgRNA-transduced OT-I cells. Numbers in graphs indicate the mean ± s.e.m. of MFI of markers on the x-axis after gating on TCF-1+ or TCF-1− subsets. Data are representative of two independent experiments (f).
